• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Luci David P

    4/22/26 4:17:53 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LUCI DAVID P

    (Last)(First)(Middle)
    C/O ACURX PHARMACEUTICALS, INC.,
    259 LIBERTY AVENUE

    (Street)
    STATEN ISLAND NEW YORK 10305

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Acurx Pharmaceuticals, Inc. [ ACXP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    XOfficer (give title below)Other (specify below)
    President and CEO
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/20/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option$2.3604/20/2026A37,100 (1)04/20/2036Common Stock37,100$037,100D
    Explanation of Responses:
    1. On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
    /s/ Kostantinos Skordalos, Power of Attorney for: David P. Luci04/22/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP

    DatePrice TargetRatingAnalyst
    11/29/2021$12.00Buy
    Maxim Group
    More analyst ratings

    $ACXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                       Tuesday, May 12, 2026Time:                       8:00 a.m. ET Toll fr

    4/20/26 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    $2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSTATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In addition, in a con

    4/16/26 4:01:00 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    $2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSTATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced

    4/16/26 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:32:30 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:59 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:33 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    SEC Filings

    View All

    Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    4/16/26 8:14:23 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Acurx Pharmaceuticals Inc.

    424B5 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    4/16/26 8:13:38 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Acurx Pharmaceuticals Inc.

    S-8 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    3/12/26 4:15:31 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sailer Carl

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    4/22/26 4:21:15 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Dean Jack H

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    4/22/26 4:20:39 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Donohue James J.

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    4/22/26 4:20:10 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

    Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    11/29/21 8:33:36 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/24 2:39:21 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/23 11:59:03 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/23 11:52:45 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                       Tuesday, May 12, 2026Time:                       8:00 a.m. ET Toll fr

    4/20/26 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                           Friday, March 13, 2026  Time:                     

    2/16/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care